

This is the Author's Pre-print version of the following article: *Luz M.T. Paz Maldonado, Víctor E. Balderas Hernández, Emilio Medina Rivero, Ana P. Barba de la Rosa, José L. Flores Flores, Leandro G. Ordoñez Acevedo, Antonio De León Rodríguez, Optimization of culture conditions for a synthetic gene expression in Escherichia coli using response surface methodology: The case of human interferon beta*, *Biomolecular Engineering*, Volume 24, Issue 2, 2007, Pages 217-222, which has been published in final form at: <https://doi.org/10.1016/j.bioeng.2006.10.001>  
This article may be used for non-commercial purposes in accordance with Terms and Conditions for Self-Archiving.



21 **Abstract**

22

23 A human interferon beta (hINF- $\beta$ ) synthetic gene was optimized and expressed in *Escherichia*  
24 *coli* BL21-SI using a vector with the T7 promoter. To determine the best culture conditions such  
25 as culture medium, temperature, cell density and inducer concentration, we used the response  
26 surface methodology and a Box-Behnken design to get the highest hINF- $\beta$  production. The  
27 maximum hINF- $\beta$  production of 61 mg l<sup>-1</sup> was attained using minimum medium and the  
28 following predicted optimal conditions: temperature of 32.5°C, cell density of 0.64, and inducer  
29 concentration of 0.30 M NaCl. We also demonstrated that the response surface methodology is  
30 effective for the optimization of recombinant proteins production using synthetic genes.

31

32

33

34 **Keywords:** Codon bias, *E. coli* BL21-SI, multiple sclerosis, response surface methodology  
35 (RSM), synthetic gene, yeast extract.

36

37 **1. Introduction**

38  
39 *Escherichia coli* is the most used host for the over-expression of recombinant proteins. Weak  
40 expression of foreign genes has been associated to the difference of codon usage between  
41 eukaryotic organisms and those preferred by *E. coli* [1]. There are strategies to overcome the  
42 problem of codon bias, such as commercial *E. coli* strains containing copies of tRNA genes,  
43 which are rare in *E. coli* but frequently used in other organisms [2]. However, there are not  
44 described *E. coli* strains containing all "rare" tRNA genes. Furthermore, the rapid degradation of  
45 mRNA proceeding from foreign cDNA causes poor expression in heterologous systems [3].  
46 Thus, the replacement of rare codons in the target gene improves the protein expression [4].  
47 However, culture conditions such as inducer concentration, cell density (induction time), and  
48 temperature also affect the recombinant proteins production [5-10].

49  
50 Human interferon  $\beta$  (hINF- $\beta$ ) is a glycoprotein involved in antiviral, antiproliferative and  
51 immunoregulatory processes. The recombinant hINF- $\beta$  has been approved for the treatment of  
52 sclerosis multiple, arthritis, genital condylomata acuminata and malignant melanoma therapy [11-  
53 14]. The glycosilated hINF- $\beta$  produced in animal cells is more stable than the non-glycosilated  
54 form produced in bacteria, however, the non-glycosilated hINF- $\beta$  is used for therapy and *in vitro*  
55 studies [15]. In this work, we assessed the production of hINF- $\beta$  using a synthetic gene optimized  
56 for its expression in *E. coli* BL21-SI [16] (a T7 system inducible with NaCl) in minimum  
57 medium. The effect of yeast extract and culture conditions such as temperature, cell density and  
58 NaCl concentration was evaluated using the response surface methodology (RSM).

59

## 60 2. Materials and methods

61

### 62 2.1. Bacterial strains and plasmids

63

64 The pCR4-585 vector containing the optimized synthetic hINF- $\beta$  gene was purchased from  
65 Entelechon GmbH (Regensburg, Germany). The *Nde*I and *Bam*HI sites were added to hINF- $\beta$   
66 synthetic gene by PCR using pCR4-585 as template and the primers sense 5'-  
67 CATATGAGCTATAACCTG-3' and anti-sense 5'-GGATCCTTAATTACGCAG-3'. The *Nde*I-  
68 hINF- $\beta$ -*Bam*HI amplified fragment was cloned in a pET12a (Novagen, Darmstadt, Germany)  
69 vector to construct pTPM13 (Fig.1), then *E. coli* BL21-SI (GIBCO, Darmstadt, Germany) was  
70 transformed by heat-shock method with the pTPM13 plasmid and transformed clones were  
71 selected on LBON medium (Luria-Bertani salt-free) with 100 mg l<sup>-1</sup> ampicillin.

72

### 73 2.2 Media and culture conditions

74

75 The minimum medium contains per liter: 5.0 g glucose, 3.5 g (NH<sub>4</sub>)<sub>2</sub>HPO<sub>4</sub>, 3.5 g KH<sub>2</sub>PO<sub>4</sub>, 1.0 g  
76 MgSO<sub>4</sub>, 40  $\mu$ g thiamine and 100 mg ampicillin. The pH was adjusted to 7.4 with NaOH prior to  
77 sterilization (20 min at 121°C). The supplemented medium consists in minimum medium with 5  
78 g l<sup>-1</sup> of yeast extract (Difco Laboratories, Franklin Lakes, NJ, USA). For all experiments, pre-  
79 inocula were grown in supplemented medium overnight at 37°C and shaken at 250 rpm. Batch  
80 cultures were carried out in 500 ml Erlenmeyer flasks with 100 ml of minimum medium or  
81 supplemented medium inoculated at a cell density of 0.20 at 620 nm, and shaken at 250 rpm.  
82 Each experiment was performed under different conditions of temperature, cell density and

83 inducer concentration as described in experimental design (Table 1).

84

### 85 *2.3. Experimental design and optimization by RSM*

86

87 To study the effect of three independent variables on the production of hINF- $\beta$  in *E. coli* BL21-  
88 SI/pTPM13, we constructed a random experimental design via Box-Behnken strategy [17]. The  
89 independent variables were temperature (factor A), cell density (factor B) and inducer  
90 concentration (factor C). Each variable was divided into three levels and twelve treatments were  
91 made in accordance to Box-Behnken factorial design (Table 1). Three additional experiments  
92 were included in order to analyze the effect of non-adjustable data. The production of hINF- $\beta$  was  
93 tested using both minimum medium and supplemented medium via the Box-Behnken design. The  
94 analysis of RSM and Analysis of Variance (ANOVA) was done using Minitab<sup>TM</sup> v 14.0 software  
95 (Minitab, Inc., Pennsylvania, USA). The significance of each coefficient (linear or quadratic) was  
96 determined with the Student's *t*-test, at 0.05 probability level. The optimal values were obtained  
97 solving the regression equation by the Newton-Raphson method and analyzing the response  
98 surface contour.

99

### 100 *2.4. Analytical methods*

101

102 Cell density was measured at 620 nm ( $OD_{620}$ ) in a Varian Cary Bio-50 spectrophotometer  
103 (Varian, Inc., Palo Alto, CA, USA). Glucose concentration was determined by the dinitro-  
104 salicylic acid (DNS) method for reducing sugars, using glucose as standard [18]. Protein  
105 concentration was determined by the method of Lowry et al. [19], using bovine serum albumin

106 (BioRad, Hercules, CA, USA) as standard. Cell samples of 2 ml were collected, centrifuged at  
107 5000 x g for 10 min, resuspended in PBS (0.1M pH 7.8) and lysed by sonication. Then, proteins  
108 were separated in a 15% sodium dodecyl sulphate polyacrylamide gel electrophoresis (15% SDS-  
109 PAGE) in a Miniprotein III System (BioRad). Proteins were stained with Coomassie Blue R-250  
110 (BioRad). For Western blot, proteins were transferred from gel onto a nitrocellulose membrane  
111 (Amersham Biosciences, Piscataway, NJ, USA) using a Semi-Dry Transblot (BioRad). The  
112 membrane was blocked with Svelty milk (3% w/v in PBS). The membrane was incubated with  
113 the rabbit anti-hINF- $\beta$  polyclonal antibody (PBL Biomedical Lab., Piscataway, NJ, USA),  
114 followed by goat anti-rabbit IgG antibody conjugated to alkaline phosphatase (BioRad), and  
115 visualized with nitro blue tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate (NBT/BCIP,  
116 Amersham Biosciences). hINF- $\beta$  concentration was measured by densitometry using the Quantity  
117 One<sup>TM</sup> v 4.5 software (BioRad). Recombinant non-glycosilated hINF- $\beta$  (PBL Biomedical Lab.)  
118 was used as standard.

119

### 120 **3. Results and discussion**

121

#### 122 *3.1. Design of hINF- $\beta$ synthetic gene*

123

124 The wild-type hINF- $\beta$  gene has 27 “rare codons” compared to those preferred by *E. coli*, from  
125 which eight are classified as low- usage codons according to Makrides classification [4]. Since,  
126 the codon context of specific genes could have adverse effects on both the quantity and quality of  
127 proteins levels [4]. Therefore, using codon bias we designed a synthetic hINF- $\beta$  gene to be  
128 expressed in *E. coli* (Fig. 2). The resultant optimized gene had 77.25% of identity with respect to

129 the wild-type gene. A summary of codon preference in *E. coli* based on the Ikemura classification  
130 [20] and codon usage in the wild-type and the optimized synthetic hINF- $\beta$  gene is shown in Table  
131 2. The most significant changes were for Arginine, Leucine, Glycine and Proline codons. Leucine  
132 is the most abundant amino acid in hINF- $\beta$  sequence, similar to “typical” *E. coli* proteins [21]. It  
133 is likely that similarity on amino acid usage would improve the performance of synthetic hINF- $\beta$   
134 in *E. coli*. Previous reports showed that expression of mammalian genes in *E. coli* increased after  
135 codon-optimization [22-24].

136

### 137 3.2. Kinetic of hINF- $\beta$ production

138

139 A typical batch culture of *E. coli* BL21-SI/pTPM13 in supplemented medium is shown in Fig. 3  
140 (experiment 8 from the Box-Behnken design). Cell density increased to a maximum of 3.9, and  
141 thereafter it remained constant until the end of the culture (Fig. 3A). During this period, glucose  
142 was consumed and cell growth ceased upon glucose depletion (Fig. 3B). The hINF- $\beta$   
143 concentration increased from 0 to 11 mg l<sup>-1</sup> after the induction with 0.15 M NaCl (Fig. 3C).  
144 Cultures maintained at other culture conditions showed a similar trend to those in Fig. 3, although  
145 the parameters measured, their maximum concentrations, and times to reach them were different  
146 in each case. Fig. 4A shows the protein patterns obtained from experiment 10. The identity of the  
147 hINF- $\beta$  was confirmed by Western blot using recombinant hINF- $\beta$  as standard (Fig. 4B). There  
148 are several reports on the production of recombinant proteins using salt induction systems in  
149 LBON [16, 25, 26]. However, in our knowledge, there are not previous reports using minimum  
150 medium for expression proteins using *E. coli* BL21-SI.

151

152

153 *3.3. Optimization of hINF-β production*

154

155 The Box-Behnken design, the experimental and predicted results for hINF-β production in  
156 minimum medium and supplemented medium are summarized in Table 1. The cultures in  
157 minimum medium showed a higher hINF-β concentration than those cultures in supplemented  
158 medium carried out under the same operational conditions. The highest hINF-β production was  
159 attained in minimum medium for the experiment 10. For the cultures using supplemented  
160 medium, the significant factors were B, A<sup>2</sup> and B<sup>2</sup> (Table 3), whereas for cultures in minimum  
161 medium the significant factors were B, A<sup>2</sup>, B<sup>2</sup>, C<sup>2</sup>, AB and AC interaction (Table 4). To estimate  
162 the optimal region of hINF-β production in minimum medium or supplemented medium, second-  
163 order models were fitted to the hINF-β observed results (data from Table 1) and the response  
164 surface graphs are shown in Fig. 5.

165 For cultures in supplemented medium the model is described by Eq. (1), where the variables are  
166 specified in their original units as follows:

167

$$168 \quad Y (\text{supplemented medium}) = -264.22 + 17.45 A + 38.33 B - 70.74 C - 0.288 A^2 - 34.90 B^2 - 37.04 C^2 \\ 169 \quad + 0.42 AB + 2.96 AC - 20.83 BC \quad (1)$$

170

171 Where Y is the response variable (hINF-β production), and A, B and C are the independent  
172 variables (temperature, cell density and inducer concentration, respectively). The standard error  
173 of the model was 3.884 and according to R<sup>2</sup> value, the predictors included in the model explain  
174 79.0% of the variance in hINF-β production. For the set of experiments in supplemented medium,

175 the maximum hINF- $\beta$  concentration was attained when temperature, cell density and inducer  
176 concentration were 31.6°C, 0.69 and 0.15 M, respectively, giving a predicted hINF- $\beta$   
177 concentration of 19 mg l<sup>-1</sup>.

178 The mathematical model representing the hINF- $\beta$  production in minimum medium in the  
179 experimental region studied is explained by Eq. (2).

180

$$181 \quad Y (\text{minimum medium}) = -1354.58 + 78.51 A + 243.33 B + 420.74 C - 1.20 A^2 - 173.18 B^2 -$$
$$182 \quad 787.04 C^2 - 0.83 AB + 1.48 AC + 12.5 BC \quad (2)$$

183

184 The standard error was 0.695 and the correlation coefficient ( $R^2$ ) was 99.9%. These values  
185 indicated a good fitting between the model and the experimental data, which explains almost the  
186 total variance in the hINF- $\beta$  production in minimum medium. In this case, the maximum  
187 concentration of hINF- $\beta$  was attained when temperature, cell density and inducer concentration  
188 were 32.5 °C, 0.64 and 0.30 M, respectively, giving a predicted hINF- $\beta$  production of 61 mg l<sup>-1</sup>.  
189 These operational conditions are the optimal values predicted to improve the hINF- $\beta$  production.  
190 The culture conditions suggested by the provider for *E. coli* BL21-SI are: LBON medium, 37°C,  
191 0.6 and 0.3M NaCl [27], which those the hINF- $\beta$  production was 12 mg l<sup>-1</sup> (data non-shown),  
192 whereas using a minimum medium and the optimal conditions proposed by the RSM, the amount  
193 of hINF- $\beta$  increased 5-fold. Goeddel et al. [28] reported a maximum hINF- $\beta$  production of 0.2 mg  
194 l<sup>-1</sup> using the wild-type gene cloned in *E. coli* and using minimum medium with casaminoacids,  
195 while we produced 95 and 305-fold more hINF- $\beta$  in supplemented medium and minimum  
196 medium, respectively. Skoko et al. [29] reported a maximum hINF- $\beta$  production of 12 mg l<sup>-1</sup> in  
197 *Pichia pastoris* cultures. Aforementioned, we attained the highest hINF- $\beta$  production using

198 minimum medium. Similar to the results obtained here, Ling [30] reported that recombinant  
199 protein ZZT2 production by *E. coli* was higher using an aminoacids-free medium than cultures  
200 supplemented with aminoacids. While Shin et al. [31] reported that the addition of yeast extract  
201 onto the culture medium enhanced the production of human proinsulin in *E. coli* cultures. Hence,  
202 we strongly suggest assaying the use of aminoacids or yeast extract to design the culture medium  
203 for the production of recombinant proteins in each expression system. RSM has been used  
204 previously for the optimization of secondary metabolite production such as xylitol by *Candida*  
205 *guilliermondii* [32], native proteins such as xylanase by *Bacillus circulans* [33] and recombinant  
206 proteins such as endochitinase by *E. coli* [9]. Our work is the first report showing that the  
207 response surface methodology is effective for the optimization of recombinant proteins  
208 production using synthetic genes.

209

## 210 **Acknowledgements**

211

212 Financial support of National Council of Science and Technology of Mexico (CONACyT) Grant  
213 J39639-Q and CONACyT-FOMIX Grant FMSLP-2002-4100. Luz M. T. Paz-Maldonado is  
214 grateful for scholarship CONACyT number 172257. We thank to Hera Andrade for English  
215 correction.

216

217 **References**

218

219 [1] Jonasson P, Liljeqvist S, Nygren P, Stahl S. Genetic design for facilitated production and  
220 recovery of recombinant proteins in *Escherichia coli*. *Biotechnol Appl Biochem* 2002;35:91-105.

221

222 [2] Sørensen HP, Mortensen KK. Advanced genetic strategies for recombinant protein expression  
223 in *Escherichia coli*. *J Biotechnol* 2005;115:113-128.

224

225 [3] De Rocher EJ, Vargo-Gogola TC, Diehn SH, Green PJ. Direct evidence for rapid degradation  
226 of *Bacillus thuringiensis* toxin mRNA as a cause of poor expression in plants. *Plant Physiol*  
227 1998;117:1445-1461.

228

229 [4] Makrides SC. Strategies for achieving high-level expression of genes in *Escherichia coli*.  
230 *Microbiol rev* 1996;60:512-538.

231

232 [5] Yildir C, Onsan ZI, KirdarB. Optimization of starting time and period of induction and  
233 inducer concentration in the production of the restriction enzyme *EcoRI* from recombinant  
234 *Escherichia coli* 294. *Turk J Chem* 1998;22:221-226.

235

236 [6] Neubauer P, Hofmann K, Holst O, Mattiansson B, Kruschke P. Maximizing the expression of  
237 a recombinant gene in *Escherichia coli* by manipulation of induction time using lactose as  
238 inducer. *Appl Microbiol Biotechnol* 1992;36:739-744.

239

240 [7] Donovan RS, Robinson CW, Glick BR. Optimizing inducer and culture conditions for  
241 expression of foreign proteins under the control of the *lac* promoter. J Ind Microbiol  
242 1996;16:145-154.

243  
244 [8] Donovan RS, Robinson CW, Glick BR. Optimizing the expression of a monoclonal antibody  
245 fragment under the transcriptional control of the *Escherichia coli lac* promoter. Can J Microbiol  
246 2000;46:532-541.

247  
248 [9] De León A, Jiménez-Islas H, González-Cuevas M, Barba de la Rosa AP. Analysis of the  
249 expression of the *Trichoderma harzianum* ech42 gene in two isogenic clones of *Escherichia coli*  
250 by response surface methodology. Process Biochem 2004;39:2173-2178.

251  
252 [10] De León, A, Breceda, GB, Barba de la Rosa, AP, Jiménez-Bremont, JF, and López-Revilla,  
253 R. Galactose induces the expression of penicillin acylase under control of the *lac* promoter in  
254 recombinant *Escherichia coli*. Biotechnol Lett 2003;25:1397-1402.

255  
256 [11] Hong J, Tejada-Simon MV, Rivera VM, Zang YC, Zhang JZ. Anti-viral properties of  
257 interferon beta treatment in patients with multiple sclerosis. Mult Scler 2002;8:237-242.

258  
259 [12] Tak PP, 't Hart BA, Kraan MC, Jonker M, Smeets TJ, Breedveld FC. The effects of  
260 interferon beta treatment on arthritis. Rheumatology 1999;38:362-369.

261

262 [13] Bornstein J, Pascal B, Zarfati D, Goldshmid N, Abramovici H. Recombinant human  
263 interferon-beta for condylomata acuminata: a randomized, double-blind, placebo-controlled study  
264 of intralesional therapy. Int J STD AIDS 1997;8:614-621.

265  
266 [14] Czarniecki CW, Fennie CW, Powers DB, Estell DA. Synergistic antiviral and  
267 antiproliferative activities of *Escherichia coli*-derived human alpha, beta, and gamma interferons.  
268 J Virol 1984;49:490-496.

269  
270 [15] Huang EY, Madireddi MT, Gopalkrishnan RV, Leszczyniecka M, Su Z, Lebedeva IV, Kang  
271 D, Jiang H, Lin JJ, Alexandre D, Chen Y, Vozhilla N, Mei MX, Christiansen KA, Sivo F,  
272 Goldstein NI, Mhashilkar AB, Chada S, Huberman E, Pestka S, Fisher PB. Genomic structure,  
273 chromosomal localization and expression profile of a novel melanoma differentiation associated  
274 (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties.  
275 Oncogene 2001;20:7051-7063.

276  
277 [16] Bhandari P, Gowrishankar J. An *Escherichia coli* host strain useful for efficient  
278 overproduction of cloned gene products with NaCl as the inducer. J Bacteriol 1997;179:4403-  
279 4406.

280  
281 [17] Montgomery DC. In Design and analysis of experiments, editor. Response surface methods  
282 and other approaches to process optimization. New York: Wiley, 1997; 372-422.

283

284 [18] Miller GL. Use of dinitrosalicylic acid reagent for determination of reducing sugar. Anal  
285 Chem 1959;31:426-428.

286

287 [19] Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurements with the Folin  
288 phenol reagent. J Biol Chem 1951;193:265-275.

289

290 [20] Ikemura T. Correlation between the Abundance of *Escherichia coli* Transfer RNAs and the  
291 Occurrence of the Respective Codons in its Protein Genes: A Proposal for a Synonymous Codon  
292 Choice that is Optimal for the *E. coli* Translational System. J Mol Biol 1981;151:389-409.

293

294 [21] Kane JF. Effects of rare codon clusters on high-level expression of heterologous proteins in  
295 *Escherichia coli*. Curr Opin Biotechnol 1995;6:494-500.

296

297 [22] Hale RS, Thompson GD. Codon optimization of the gene encoding a domain from human  
298 type 1 neurofibromin protein results in a threefold improvement in expression level in  
299 *Escherichia coli*. Protein Expression Purif 1998;12:185-188.

300

301 [23] Li Y, Chen CX, von Specht BU, Hahn HP. Cloning and hemolysin-mediated secretory  
302 expression of a codon-optimized synthetic human interleukin-6 gene in *Escherichia coli*. Protein  
303 Expression Purif 2002;25:437-447.

304

305 [24] Li A, Kato Z, Ohnishi H, Hashimoto K, Matsukuma E, Omoya K, Yamamoto Y, Kondo N.  
306 Optimized gene synthesis and high expression of human interleukin-18. *Protein Expression Purif*  
307 2003;32:110-118.  
308

309 [25] Bouley R, Breton S, Sun T, McLaughlin M, Nsumu NN, Lin HY, Ausiello DA, Brown D.  
310 Nitric oxide and atrial natriuretic factor stimulate cGMP-dependent membrane insertion of  
311 aquaporin 2 in renal epithelial cells. *J Clin Invest* 2000;106:1115-1126.  
312

313 [26] Bell PJJ, Sunna A, Gibbs MD, Curach NC, Nevalainen H, Bergquist PL. Prospecting for  
314 novel lipase genes using PCR. *Microbiol* 2002;148:2283–2291.  
315

316 [27] Donahue RA, Jr, Bebee RL. BL21-SI competent cells for protein expression in *E. coli*.  
317 *Focus* 1999;21:49-51.  
318

319 [28] Goeddel DV, Shepard HM, Yelverton E, Leung D, Crea R. Synthesis of human fibroblast  
320 interferon by *E. coli*. *Nucleic Acids Research* 1980;8:4057-4074.  
321

322 [29] Skoko N, Argamante B, Kovacevic N, Tisminetzky SG, Glisin V, Ljubijankic G. Expression  
323 and characterization of human interferon- $\beta$ 1 in the methylotrophic yeast *Pichia pastoris*.  
324 *Biotechnol Appl Biochem* 2003;38:257-265.  
325

326 [30] Ling H. Physiology of *Escherichia coli* in batch and fed-batch cultures with special  
327 emphasis on amino acid and glucose metabolism. Doctoral thesis. Department of Biotechnology,

328 Royal Institute of Technology, Stockholm, Sweden 2002. [Accessed 26 October 2005].  
329 <http://media.lib.kth.se:8080/dissengrefhit.asp?dissnr=3334>

330  
331 [31] Shin CS, Hong MS, Bae CS, Lee J. Enhanced production of human mini-proinsulin in fed-  
332 batch cultures at high cell density of *Escherichia-coli* BL21 (DE3) (pET-3aT2M2). *Biotechnol*  
333 *Prog* 1997;13:249-257.

334  
335 [32] Silva CJSM, Roberto IC. Optimization of xylitol production by *Candida guilliermondii* FTI  
336 20037 using response surface methodology. *Process Biochem* 2001;36:1119-1124.

337  
338 [33] Bocchini DA, Alves-Prado HF, Baida LC, Roberto IC, Gomes E, Da Silva R. Optimization  
339 of xylanase production by *Bacillus circulans* D1 in submerged fermentation using response  
340 surface methodology. *Process Biochem* 2002;38:727-31.

341  
342  
343  
344  
345  
346  
347  
348  
349  
350

351 **Figure captions**

352

353 **Fig. 1.** Schematic representation of pTPM13. The T7 promoter drives the hINF- $\beta$  synthetic gene.

354

355 **Fig. 2.** Alignment of nucleotide sequence of wild-type and the optimized synthetic hINF- $\beta$  gene  
356 used in this work.

357

358 **Fig. 3.** Growth kinetics of *E. coli* BL21-SI/pTPM13 in supplemented medium for the experiment  
359 8: A) Cell density [ $\bullet$ ](OD<sub>620nm</sub>), B) Glucose concentration [ $\blacksquare$ ] (g l<sup>-1</sup>), C) hINF- $\beta$  concentration  
360 [ $\blacktriangle$ ](mg l<sup>-1</sup>). Arrow shows induction time with NaCl.

361

362 **Fig. 4.** Protein patterns and Western-Blot analysis for hINF- $\beta$  obtained in *E. coli* BL21-  
363 SI/pTPM13 cultures from the experiment 10. A) Typical protein patterns in minimum medium.  
364 Lane 1, protein ladder (Invitrogen); lane 2, culture before induction; lanes 3 to 7, total cell protein  
365 of six samples after induction. B) Western-Blot for samples described above. Lane 1, standard  
366 hINF- $\beta$  (PBL Biomedical Lab); lane 2-7, six samples after induction.

367

368 **Fig. 5.** Response surface plot of hINF- $\beta$  concentration as a function of temperature and cell  
369 density: A) Cultures in supplemented medium induced with 0.15M NaCl. B) Cultures in  
370 minimum medium induced with 0.30 M NaCl.

371

372